Werfen, a Barcelona-based manufacturer and distributor of specialized diagnostic instruments, related reagents, automation work cells, and data management solutions, has acquired Immucor, a USA-based transfusion and transplant in vitro diagnostics company, from TPG.
Immucor is a provider of transfusion and transplantation diagnostic products worldwide.
The deal is expected to close during the first half of 2023 and total $2 billion. The acquisition will allow Werfen to expand its portfolio.
Allen & Overy’s cross-border team from Madrid, London, and New York offices has advised BNP Paribas, BBVA, CaixaBank, and HSBC as arrangers in the financing to Werfen for the acquisition of Immucor, Inc. in the US, for €2 billion. The A&O Madrid office team was led by partners Charles Poole-Warren and Jimena Urretavizcaya, along with senior associate Sofía Sánchez-Calero, while the London office team was led by partner Greg Brown and the New York office team was led by partner Todd Koretzky, along with lawyers Livia Talenti and Jason Woolmer.
On the other hand, Deloitte has advised Werfen on the acquisition of the US company Immucor.
Deloitte Legal’s team was led by partner Josep Serrano and principal associate Xavier Betran. On this deal, a Deloitte Financial Advisory team has also participated.